Company
Headquarters: Shanghai, China
Employees: 12,946
CN¥15.61 Billion
CNY as of Jan. 1, 2025
US$2.14 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Shanghai Shyndec Pharmaceutical Co., Ltd. manufactures drug preparation products in China and internationally. It focuses on anti-infection, cardiovascular and cerebrovascular, anti-tumor, metabolism, and endocrine areas. The company was founded in 1996 and is based in Shanghai, China.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥11.50 B |
| EBITDA | CN¥1.81 B |
| Gross Profit TTM | CN¥4.38 B |
| Profit Margin | 9.41% |
| Operating Margin | 18.77% |
| Quarterly Revenue Growth | -3.10% |
Shanghai Shyndec Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SSE: 600420 wb_incandescent